Mera Pharmaceuticals, Inc.
MRPI · OTC
10/31/2011 | 7/31/2011 | 4/30/2011 | 1/31/2011 | |
|---|---|---|---|---|
| Revenue | $64 | $87 | $87 | $65 |
| % Growth | -26.4% | -0.5% | 35% | – |
| Cost of Goods Sold | $2 | $0 | $10 | $4 |
| Gross Profit | $62 | $87 | $77 | $61 |
| % Margin | 96.5% | 99.7% | 88.3% | 94.5% |
| R&D Expenses | $45 | $41 | $49 | $38 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $118 | $64 | $64 | $60 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $2 | $1 | $3 |
| Operating Expenses | $165 | $107 | $115 | $101 |
| Operating Income | -$104 | -$20 | -$38 | -$40 |
| % Margin | -162% | -23.1% | -43.5% | -61.1% |
| Other Income/Exp. Net | -$2 | $1 | -$1 | $1 |
| Pre-Tax Income | -$106 | -$19 | -$39 | -$38 |
| Tax Expense | -$3 | -$4 | -$4 | -$3 |
| Net Income | -$102 | -$16 | -$35 | -$35 |
| % Margin | -159.9% | -18.1% | -40.2% | -53.7% |
| EPS | -0 | -0 | -0.01 | -0 |
| % Growth | -595.6% | 99.7% | -9,900% | – |
| EPS Diluted | -0 | -0 | -0.01 | -0 |
| Weighted Avg Shares Out | 552,535 | 547,770 | 547,770 | 547,770 |
| Weighted Avg Shares Out Dil | 552,535 | 547,770 | 547,770 | 547,770 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $2 |
| Depreciation & Amortization | $2 | $2 | $1 | $3 |
| EBITDA | -$101 | -$16 | -$37 | -$34 |
| % Margin | -158.7% | -18.3% | -42% | -52.2% |